New antibody therapy aims to control advanced prostate cancer
NCT ID NCT07192614
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This study tests an experimental drug called AZD6621 for men with metastatic prostate cancer that has spread. The drug is designed to help the immune system attack cancer cells. The trial has two parts: first, finding the safest dose, then testing that dose in more people to see if it shrinks tumors or lowers PSA levels. About 52 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
NOT_YET_RECRUITINGOrlando, Florida, 32806, United States
-
Research Site
RECRUITINGTampa, Florida, 33612, United States
-
Research Site
WITHDRAWNBoston, Massachusetts, 02114, United States
-
Research Site
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
Research Site
RECRUITINGCommack, New York, 11725, United States
-
Research Site
RECRUITINGProvidence, Rhode Island, 02903, United States
-
Research Site
NOT_YET_RECRUITINGGhent, 9000, Belgium
-
Research Site
NOT_YET_RECRUITINGToronto, Ontario, M4N 3M5, Canada
-
Research Site
NOT_YET_RECRUITINGQuébec, G1J 1Z4, Canada
-
Research Site
NOT_YET_RECRUITINGBeijing, 100142, China
-
Research Site
SUSPENDEDChengdu, 610041, China
-
Research Site
SUSPENDEDGuangzhou, 510060, China
-
Research Site
NOT_YET_RECRUITINGNanjing, 2100008, China
-
Research Site
RECRUITINGChūōku, 104-0045, Japan
-
Research Site
RECRUITINGHirakata-shi, 573-1191, Japan
-
Research Site
NOT_YET_RECRUITINGKashiwa, 277-8577, Japan
-
Research Site
NOT_YET_RECRUITINGAmsterdam, 1066CX, Netherlands
-
Research Site
NOT_YET_RECRUITINGMaastricht, 6229 HX, Netherlands
-
Research Site
RECRUITINGSeoul, 03080, South Korea
-
Research Site
RECRUITINGSeoul, 5505, South Korea
-
Research Site
NOT_YET_RECRUITINGBarcelona, 8035, Spain
-
Research Site
NOT_YET_RECRUITINGL'Hospitalet de Llobregat, 08908, Spain
-
Research Site
NOT_YET_RECRUITINGMadrid, 28041, Spain
-
Research Site
RECRUITINGCambridge, CB2 0QQ, United Kingdom
-
Research Site
NOT_YET_RECRUITINGManchester, M20 4BX, United Kingdom
Conditions
Explore the condition pages connected to this study.